Zoetis Inc. (NYSE:ZTS) Stake Reduced by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,167 shares of the company's stock after selling 1,746 shares during the period. Mutual of America Capital Management LLC's holdings in Zoetis were worth $8,825,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ZTS. Howard Capital Management Group LLC grew its stake in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company's stock valued at $20,489,000 after acquiring an additional 883 shares in the last quarter. Financial Advocates Investment Management grew its stake in Zoetis by 6.2% during the 3rd quarter. Financial Advocates Investment Management now owns 3,451 shares of the company's stock valued at $674,000 after purchasing an additional 200 shares in the last quarter. US Bancorp DE grew its stake in Zoetis by 0.4% during the 3rd quarter. US Bancorp DE now owns 151,819 shares of the company's stock valued at $29,665,000 after purchasing an additional 637 shares in the last quarter. Hills Bank & Trust Co grew its stake in Zoetis by 13.5% during the 3rd quarter. Hills Bank & Trust Co now owns 2,082 shares of the company's stock valued at $407,000 after purchasing an additional 247 shares in the last quarter. Finally, Lebenthal Global Advisors LLC grew its stake in Zoetis by 9.2% during the 3rd quarter. Lebenthal Global Advisors LLC now owns 1,266 shares of the company's stock valued at $247,000 after purchasing an additional 107 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Stock Performance

NYSE:ZTS traded down $2.94 during mid-day trading on Wednesday, hitting $166.96. The stock had a trading volume of 3,667,422 shares, compared to its average volume of 3,280,360. The stock has a market capitalization of $74.76 billion, a price-to-earnings ratio of 30.52, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a 50 day simple moving average of $166.57 and a 200-day simple moving average of $176.99. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.